Overview

Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.

Status:
Active, not recruiting

Trial end date:
2022-04-29

Target enrollment:

Participant gender:

Summary

Dose finding study to determine the safety and tolerability of Sotatercept (ACE-011) in adults with Beta (β)-Thalassemia

Phase:

Phase 2

Details

Lead Sponsor:

Celgene
Celgene Corporation